U.S. markets open in 5 hours 39 minutes
  • S&P Futures

    3,988.50
    +18.25 (+0.46%)
     
  • Dow Futures

    33,969.00
    +98.00 (+0.29%)
     
  • Nasdaq Futures

    11,694.50
    +78.25 (+0.67%)
     
  • Russell 2000 Futures

    1,844.40
    +11.60 (+0.63%)
     
  • Crude Oil

    78.92
    +1.68 (+2.18%)
     
  • Gold

    1,770.00
    +14.70 (+0.84%)
     
  • Silver

    21.46
    +0.33 (+1.59%)
     
  • EUR/USD

    1.0392
    +0.0047 (+0.46%)
     
  • 10-Yr Bond

    3.7030
    0.0000 (0.00%)
     
  • Vix

    22.01
    +1.51 (+7.37%)
     
  • GBP/USD

    1.2060
    +0.0095 (+0.79%)
     
  • USD/JPY

    138.0080
    -0.8930 (-0.64%)
     
  • BTC-USD

    16,501.02
    +256.79 (+1.58%)
     
  • CMC Crypto 200

    389.72
    +9.43 (+2.48%)
     
  • FTSE 100

    7,533.69
    +59.67 (+0.80%)
     
  • Nikkei 225

    28,027.84
    -134.99 (-0.48%)
     

Positive week for Senti Biosciences, Inc. (NASDAQ:SNTI) institutional investors who lost 75% over the past year

To get a sense of who is truly in control of Senti Biosciences, Inc. (NASDAQ:SNTI), it is important to understand the ownership structure of the business. With 37% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Last week's US$55m market cap gain would probably be appreciated by institutional investors, especially after a year of 75% losses.

Let's delve deeper into each type of owner of Senti Biosciences, beginning with the chart below.

See our latest analysis for Senti Biosciences

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Senti Biosciences?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Senti Biosciences. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Senti Biosciences, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Senti Biosciences. Bayer Aktiengesellschaft is currently the largest shareholder, with 14% of shares outstanding. With 13% and 10% of the shares outstanding respectively, BNY Mellon Asset Management and New Enterprise Associates, Inc. are the second and third largest shareholders. Additionally, the company's CEO Timothy Lu directly holds 3.7% of the total shares outstanding.

To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

Insider Ownership Of Senti Biosciences

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our most recent data indicates that insiders own a reasonable proportion of Senti Biosciences, Inc.. Insiders own US$13m worth of shares in the US$109m company. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public-- including retail investors -- own 22% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

Private equity firms hold a 16% stake in Senti Biosciences. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Public Company Ownership

Public companies currently own 14% of Senti Biosciences stock. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 5 warning signs with Senti Biosciences (at least 2 which are a bit unpleasant) , and understanding them should be part of your investment process.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here